# Il ruolo della proprietà intellettuale nell'evoluzione della giovane Start-up







Med-Tech start-up, spin-off of University of Sannio, Benevento ITALY

## Our startup

Often Medical was founded in 2018 by a multidisciplinary research team from:

Optoelectronics and Photonics Group at the Department of Engineering of the University of Sannio in Benevento (decades of experience in developing advanced fiber optic sensors for industrial applications)

Department of Medical Surgical Sciences and Medicine Translation of the University of Rome Sapienza (experts in algology and invasive and mini-invasive techniques in pain therapy)

in collaboration with DayOne, incubator of high tech start-ups from European research centers








## The epidural Anesthesia

#### The most commonly performed procedure for pain relief



#### The standard of care

Loss of resistance (LOR) technique



1. A needle is manually inserted into the epidural space (ES). On entering the ES, an abrupt drop of resistance on the plunger is perceived.

'blind' technique



2. A catheter is inserted into the patient's back through the needle and left in position. The drug is administered through the catheter

### The clinical need

Doctors still use **manual approaches** for performing epidurals

The success depends on the operator experience

## Failure rates up to 30% in clinical practice

British Journal of Anaesthesia 109, (2) 144-54 (2012)

In Italy, Extra cost of about 300M/year for the National Health Service



## The market

# It is estimated that each year about 3% of people undergoes an epidural

Number of people receiving epidurals annually										
	A= # people	B= # epid/yr	B/A							
USA			3.4%							
ITALY			2.6%							
EUROPE	740 M	22.2 M	3%							

quote from the New England Journal of Medicine in July 2014









**Epidural Market is continuously growing** 

#### GLOBAL EPIDURAL ANESTHESIA SYSTEMS MARKET, BY PRODUCT TYPE 2017-2028 (USD MILLION)

Product	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	CAGR %
Catheters	351.4	391.1	429.1	470.0	514.1	561.3	612.0	665.1	721.8	782.3	846.5	914.7	8.68%
Needles	395.1	441.0	485.4	533.4	585.2	641.0	701.0	764.4	832.1	904.6	982.0	1,064.5	9.02%
Accessories	206.6	230.9	254.5	279.9	307.4	337.1	369.0	402.8	438.9	477.6	519.0	563.1	9.13%
Total	953.1	1,063.0	1,169.0	1,283.4	1,406.7	1,539.4	1,682.0	1,832.3	1,992.9	2,164.5	2,347.5	2,542.3	8.92%

Source: Trade Associations, Annual Reports, Government & Regulatory Bodies, Paid Databases.



## Competitors

#### Passive devices

#### **Episure**®



http://www.indigo-orb.com/products/episure-epidural-LOR-syringe.php

### Epidrum ®



http://www.exmoorinnovations.co.uk/index .php/epidrum/epidrum-what-is-it

#### Tuoren LOR®



http://www.tuoren.com/en/index.php?s= /product/show/id/1499.html

- o Simple
- Visual feedback
- High compatibility with standard kits and procedures


#### No catheter placement monitoring!

#### Active devices



https://www.milestonescientific.com/products/compuflo-epidural

#### **APAD**®



http://www.qrsinternational.nl/medical-devices/apad-acoustic-puncture-assist-device/

#### **EPI Detection®**




http://saeummeditec.com/


- Visual/acoustic feedback
- Injection record database (except Epidetection)
- Compatibility with standard kits and procedures



## Our solution

We developed an innovative system based on a proprietary **optical fiber sensor technology** 





Our smart needle measures in real time the pressure during the insertion making the whole procedure objective and less operator-dependent






- Idea: The project is aimed to meet a clear clinical need raised by anesthesiologists
- **First patent**: we recognize that the idea is new and compatible with an industrial device able to have a strong impact in the specific medical sector with an **interesting market**-> this pushed us to write a patent (deposited in Italy, one year priority worldwide) but...:
- **Critical issue**: the patent is written with a strong focus on the concept more than on the technical aspects that are still undefined
- **First prototype**: a preliminary mock-up is fabricated and first test are carried out on an epidural phantom tissue used for training purposes.





- First tests on animal (in-vivo): our prototype is tested on animals (study authorized by Italian Ministry of Health)
  Phanotm and Animals studies help us to recognize that the original idea and prototype need a significant review
- Second Patent: we give up with the first patent and prepare, in collaboration with leading European intellectual property firm a new draft of the patent including all the technical specifications collected during tests performed on both phantom tissue and animals.
- The second patent focuses on the device instead of the concept and it is much more detailed than the first one
- Based on our experience, the technical details are the real value of the intellectual property





- The second prototype is developed according to all the inputs received by anestesiologists (our partners and opinion leaders) who used our device. Phantom tests confirm our performance expectations and the advances in respect to the first prototype.
- International Patent: the second patent works so that we decided to go for a PCT





- Our team meets a **startup incubator (Day One srl)** during the event «User-driven innovation: a new way to develop technologies and startups together with large companies» organized by Unisannio;
- The presence of the patent is of fundamental importance to win the selection process.
- Thanks to the collaboration with the incubator we prepared a business plan and started to look around for fundings.
- We apply to the call "Bando supporto allo sviluppo di spin-off e startup innovative" POR Campania FESR 2014-2020 (project value 500k, co-financing 35%)
- The availability of an (international) patent gives scores and positive comments during the process evaluation.



## Proof of Concept Animal Study

#### Fully functional prototype



1. Epidural phantom tissue

2. In-vivo test on pigs



Publications on scientific journals

Best Poster Award
Chemical, Environmental,
Biological and Medical Sensors



IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS VOL. 23 NO. 2 MARCH/APRIL 2012

# Optical Guidance Systems for Epidural Space Identification

Benito Carotenuto, Alberto Micco, Armando Ricciardi, Ezio Amorizzo, Marco Mercieri, Antonello Cutolo, and Andrea Cusano


(Invited Paper)

#### *In-vivo* tests on animals

authorized by Italian Ministry of Health (auth. N. 554/2017)


1. Needle placement


64 procedures
100% of accuracy





2. Catheter placement





Research Article Vol. 10, No. 3 | 1 Mar 2019 | BIOMEDICAL OPTICS EXPRESS 1351

Biomedical Optics EXPRESS

Optical fiber technology enables smart needles for epidurals: an *in-vivo* swine study

BENITO CAROTENUTO, ARMANDO RICCIARDI, ABERTO MICCO, EZIO AMORIZZO, MARCO MERCIERI, ANTONELLO CUTOLO, AND ANDREA CUISANO 1.4



Article

#### **Smart Optical Catheters for Epidurals**

Benito Carotenuto <sup>1</sup>, Armando Ricciardi <sup>1,\*</sup> <sup>0</sup>, Alberto Micco <sup>1</sup>, Ezio Amorizzo <sup>2</sup>, Marco Mercieri <sup>2</sup> <sup>0</sup>, Antonello Cutolo <sup>1</sup> and Andrea Cusano <sup>1,\*</sup>






- The project is funded and finally the startup is established.
- New projects are submitted to the ERC (European Research Council) -> we obtain
  the 'seal of excellence' certificate that will give us the possibility to win new public
  grants...
- Again, the availability of an (international) patent gives scores and positive comments during the process evaluation.
- We start to meet Venture Capital (VC) firms at both national and international level







Often Medical is financed by the Vertis Venture 3 Tech Transfer, a venture Capital fund managed by Vertis SGR and Venture Factory (seed fund 575k).


During negotiations, the investors considered the presence of an international patent a conditio sine qua non for the equity injection. Often Medical has the exclusive license of the patent.

In the mean time the patent is granted in Europe (20 countries), United States, Canada and China.

Patent costs incurred to date are about 100Keuro / Patent manteinance expenses are about 20k/per year



## Our future Go to market



Recently, Often Medical was the first among the startups that can be financed within the call "Campania Start Up 2020" - PO FESR 2014-2020 (project value 420k, co-financing 30%) *Again, the availability of an (international) patent provides higher score and positive comments during the process evaluation.* 



# Awards and Endorsement

















Runner-up in the life science cathegory in 2019

Finalist at Premio Gaetano Marzotto 2019 Funded by a VC 2019

Grant winner «Campania startup» 2017 and 2020 editions

Selected for the call 'Campania Tech Revolution 2020'

#### Our project has been endorsed by

Dr. Ezio Amorizzo



Dr. Marco Mercieri





Dr. Enrico Barbara



Dr. Andrea Tognù





President and Incoming President of



and many others...



## The certificates



of the United States Satent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of tare have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Sherfore, this United States

Market States

Market

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 u.s.c.  $\iota_3(a)(z)$  or (c)(1), subject to the payment of maintenance fees as provided by 35 u.s.c.  $\iota_4(b)$ . See the Maintenance Fee Notice on the inside of the cover.

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



## Thank you for your kind attention





#### 国家知识产权局

#### 100083

北京市海淀区学清路 38 号 (B 座)21 层 2108 北京安信方达知识产权 代理有限公司

1 (理有限公司 张瑞(82730790) 杨明钊(82730790) 发文日:

2020年12月07日

申请号或专利号: 201680074700.2 发文序号: 2020120200093540

申请人或专利权人: 埃齐奥·阿莫里佐 安德里亚·库萨诺 安东内洛·库托洛 马尔科·梅尔切里 阿尔贝 托·米科 阿尔曼多·里恰尔迪

发明创造名称: 用于医用针插入的引导系统

#### 办理登记手续通知书

根据专利法实施细则第 54 条及国家知识产权局第 272 号公告的规定,申请人应当于 <u>2021</u> 年 <u>02</u> 月 <u>22</u> 日 之前缴纳以下费用:

第5年度年费 1200.0元 无费减 (减缴标记)

专利证书印花税 5.0 元 共计 1205.0 元

附已缴费用情况: 年费 0.0 元,专利证书印花税 0.0 元。

申请人按期缴纳上述费用的,国家知识产权局将在专利登记簿上登记专利权的授予,颁发专利证书,并

予以公告。专利权自公告之日起生效。

申请人期满未缴纳或者未缴足上述费用的,视为放弃取得专利权的权利。

提示:

专利费用可以通过网上缴费、邮局或银行汇款缴纳,也可以到国家知识产权局面缴。

网上缴费:电子申请注册用户可登陆 http://cponline.cnipa.gov.cn,并按照相关要求使用网上缴费系统缴纳。

邮局汇款:收款人姓名:国家知识产权局专利局收费处,商户客户号:110000860。

银行汇款: 开户银行: 中信银行北京知春路支行: 户名: 国家知识产权局专利局: 账号: 7111710182600166032。

按照财税[2019]13 号及京财税[2019]196 号通知,增值税小规模纳税人减半按 2.5 元缴纳印花税。

审 查 员;自动审查 审查部门;专利局初审及流程管理部

联系电话: 010-62084704

纸件申请,园函请客。100088 北京市海淀区蓟门桥西土城路 6 号 国家知识产权局专利局受理处收 电子申请,应当通过电子专利申请系统以电子文件形式提交相关文件。除另有规定外,以纸件等其他形式提交的 文件组为未提介







Where we are:

Legal:

viale Mellusi 63/65 82100 Benevento, Italy

**Operative:** 

via Manfredi di Svevia 2A 82100 Benevento, Italy Contacts

Mobile:

+39 339 7782935

**Email:** 

info@often-medical.com often-medical@pec.it

often-medical.com f in